Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
57 studies found for:    IL-2 SELECT
Show Display Options
Rank Status Study
1 Active, not recruiting The High-Dose Aldesleukin (IL-2) "Select" Trial for Patients With Metastatic Renal Cell Carcinoma
Condition: Metastatic Renal Cell Carcinoma
Intervention: Drug: aldesleukin (Proleukin)
2 Active, not recruiting IL-2 "SELECT" Tissue Collection Protocol in Patients With Advanced Melanoma
Condition: Malignant Melanoma
Intervention: Drug: IL-2
3 Recruiting Ultra-Low Dose IL-2 Therapy as GVHD Prophylaxis in Haploidentical Allogeneic Stem Cell Transplantation
Conditions: Acute Lymphoblastic Leukemia (ALL);   Acute Myelogenous Leukemia (AML);   Chronic Lymphocytic Leukemia (CLL);   Chronic Myelogenous Leukemia (CML);   MDS
Intervention: Device: CliniMACS CD34 selection system
4 Terminated Immunotherapy Using 41BB Selected Tumor Infiltrating Lymphocytes for Patients With Metastatic Melanoma
Conditions: Melanoma;   Skin Cancer
Interventions: Drug: Aldesleukin;   Drug: Fludarabine;   Drug: Cylcophosphamide;   Biological: 4-1BB Selected TIL
5 Withdrawn CD3/CD19 Depleted or CD3 Depleted/CD56 Selected Haploid Donor Natural Killer Cell Treatment in Older AML in First Complete Remission
Condition: Acute Myelogenous Leukemia
Interventions: Biological: CD3-/CD19- natural killer cells;   Biological: CD3-CD56+ natural killer cells;   Device: CliniMACS® CD3 and CD19 Reagent System;   Device: CliniMACS® CD56 Reagent System;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Drug: Aldesleukin
6 Recruiting A Pilot Study of Immunotherapy Including Haploidentical NK Cell Infusion Following CD133+ Positively-Selected Autologous Hematopoietic Stem Cells in Children With High Risk Solid Tumors or Lymphomas
Conditions: Neuroblastoma;   Lymphoma;   High-risk Tumor
Interventions: Device: CD133+ selected autologous stem cell infusion;   Biological: IL-2;   Biological: hu14.18K322A;   Drug: Busulfan;   Drug: Melphalan;   Biological: GM-CSF;   Drug: Bendamustine;   Drug: Etoposide;   Drug: Cytarabine;   Drug: Carboplatin;   Device: Haploidentical natural killer cell infusion;   Biological: G-CSF;   Drug: Etoposide phosphate
7 Recruiting Phase I of Infusion of Selected Donor NK Cells After Allogeneic Stem Cell Transplantation
Condition: Hematological Malignancy
Intervention: Biological: NK Cell infusion
8 Completed Study of Heat Shock Protein-Peptide Complex (HSPPC-96) Versus IL-2/DTIC for Stage IV Melanoma
Condition: Malignant Melanoma
Intervention: Drug: HSPPC-96 or Oncophage
9 Recruiting Induction of Regulatory t Cells by Low Dose il2 in Autoimmune and Inflammatory Diseases
Conditions: Rheumatoid Arthritis;   Ankylosing Spondylitis;   Systemic Lupus Erythematosus;   Psoriasis;   Behcet's Disease;   Wegener's Granulomatosis;   Takayasu's Disease;   Crohn's Disease;   Ulcerative Colitis;   Autoimmune Hepatitis;   Sclerosing Cholangitis
Intervention: Drug: Interleukin 2
10 Completed
Has Results
Effect of Intermittent Aldesleukin Treatment With or Without Anti-HIV Drugs in HIV Infected People
Condition: HIV Infections
Intervention: Drug: IL-2
11 Completed
Has Results
An International Study to Evaluate Recombinant Interleukin-2 in HIV Positive Patients Taking Anti-retroviral Therapy
Condition: HIV Infections
Intervention: Drug: Recombinant interleukin-2 (rIL-2)
12 Recruiting PD-1 Knockout Engineered T Cells for Metastatic Non-small Cell Lung Cancer
Condition: Metastatic Non-small Cell Lung Cancer
Interventions: Drug: Cyclophosphamide;   Other: PD-1 Knockout T Cells;   Drug: Interleukin-2
13 Completed Immune Mobilization of Autologous Peripheral Blood Stem Cells Using Interleukin-2 and GM-CSF
Conditions: Non-Hodgkin's Lymphoma;   Hodgkin's Disease;   Multiple Myeloma;   Other Plasma Cell Dyscrasia (Waldenstrom, Amyloidosis);   Leukemia
Interventions: Drug: GM-CSF;   Drug: IL-2
14 Unknown  Peptide Vaccination Associated With Tumoral Immunomodulation in Patients With Advanced Metastatic Melanoma
Condition: Metastatic Melanoma
Intervention: Drug: Vaccine MAGE-3.A1 peptide, or the NA17.A2 peptide + IL-2, IFN-α and GMCSF, Imiquimod.
15 Not yet recruiting PD-1 Knockout Engineered T Cells for Muscle-invasive Bladder Cancer
Condition: Invasive Bladder Cancer Stage IV
Interventions: Biological: PD-1 Knockout T Cells;   Drug: Cyclophosphamide;   Drug: IL-2
16 Not yet recruiting PD-1 Knockout Engineered T Cells for Castration Resistant Prostate Cancer
Condition: Hormone Refractory Prostate Cancer
Interventions: Biological: PD-1 Knockout T Cells;   Drug: Cyclophosphamide;   Drug: IL-2
17 Not yet recruiting PD-1 Knockout Engineered T Cells for Metastatic Renal Cell Carcinoma.
Condition: Metastatic Renal Cell Carcinoma
Interventions: Biological: PD-1 Knockout T Cells;   Drug: Cyclophosphamide;   Drug: IL-2
18 Recruiting Dose Escalation and Expansion Study of GSK3359609 in Subjects With Selected Advanced Solid Tumors (INDUCE-1)
Condition: Cancer
Interventions: Drug: GSK3359609 IV infusion;   Drug: Pembrolizumab 200 mg IV infusion
19 Completed Vaccine Treatment in Combination With IL-2 and Treated Lymphocytes for Advanced Melanoma
Condition: Melanoma
Interventions: Drug: IL-2;   Drug: gp100:209-217;   Drug: OKT3;   Drug: rF-go 100P209;   Drug: Montanide ISA 51
20 Completed Pilot Study of Expanded, Donor Natural Killer Cell Infusions for Refractory Non-B Lineage Hematologic Malignancies and Solid Tumors
Conditions: Leukemia, Myeloid, Acute;   Leukemia, Lymphocytic, Acute, T-Cell;   Juvenile Myelomonocytic Leukemia Lymphoblastic;   T-cell Lymphoblastic Lymphoma;   Myelodysplastic Syndrome
Interventions: Procedure: Haploidentical donor derived natural killer cell infusion;   Drug: Chemotherapy;   Device: CliniMACS

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.